Bicara Therapeutics Inc. (BCAX) stock
BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.75−0.27 (-2.69%)
Close on Nov 16, 2026Market cap $645.19MP/E –Yield –
Bicara Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Bicara Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2025 was $112.00M, up 106.6% year over year. For fiscal 2024 it was $63.60M, up 107.8% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $63.60M | +107.8% |
| FY2023 | Dec 31, 2023 | $30.60M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | $33.00M | +107.5% |
| Q2 FY2025 | Jun 30, 2025 | $24.80M | +57.0% |
| Q1 FY2025 | Mar 31, 2025 | $34.30M | +185.8% |
| Q4 FY2024 | Dec 31, 2024 | $19.90M | +89.5% |
| Q3 FY2024 | Sep 30, 2024 | $15.90M | +130.4% |
| Q2 FY2024 | Jun 30, 2024 | $15.80M | – |
| Q1 FY2024 | Mar 31, 2024 | $12.00M | – |
| Q4 FY2023 | Dec 31, 2023 | $10.50M | – |
| Q3 FY2023 | Sep 30, 2023 | $6.90M | – |
See a number that looks wrong?